Solural Pharma ApS
Solural Pharma ApS is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
Senicapoc in patients with Progressive Fibrotic ILD (Interstitial Lung Disease) or IPF (Idiopathic Pulmonary Fibrosis) to prevent progression.
Sponsor Lillebaelt Hospital
- Start (EU)
- Latest update
- Estimated end
An open-label phase II prospective clinical trial to investigate safety, tolerability, maximum tolerated dose and anti-tumor effect for SCO-101 in combination with FOLFIRI as a safe and efficient treatment modality in metastatic or advanced colorectal cancer (mCRC) patients with acquired FOLFIRI resistant cancer disease
Sponsor Scandion Oncology A/S
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Solural Pharma ApS?
The 2026-10-09 snapshot links Solural Pharma ApS to 2 distinct CTIS trials. Recorded services include Medicinal product management. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Solural Pharma ApS?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Solural Pharma ApS conducted?
The linked trials record locations in 3 countries, including Denmark, Estonia, Spain. These are trial locations, not confirmed office locations or countries where Solural Pharma ApS delivered services.
What can this page tell me about Solural Pharma ApS's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Solural Pharma ApS. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Solural Pharma ApS